Loading...

Loading...

Alliances Key For Quick, Efficient COVID-19 Vaccine Development
By Miriam Bello - Thu, 11/05/2020 - 15:09
GSK is a global leader in vaccine development. These are the company’s current developments on COVID-19.
https://mexicobusiness.news/tag/glaxosmithkline
More Health
Digital Medicine: Slow but Steady Path to Full Digitalization
By Miriam Bello - Thu, 10/22/2020 - 11:56
GSK is looking for most doctors to join the digital ecosystem in the medium term.
Vaccination Scenarios in Mexico
By Miriam Bello - Tue, 09/08/2020 - 12:58
Mexico’s vaccination blues are undeniable. The country could still take advantage of lingering production opportunities to exploit this market.
Mexico’s Participation In Sanofi’s COVID-19 Vaccine Trial
By Miriam Bello - Fri, 07/31/2020 - 11:41
The Minister of Foreign Affairs revealed that Mexico will join Phase 3 of trials on Sanofi’s COVID-19 vaccine.
COVID-19 Research Pushes Through
By Miriam Bello - Mon, 07/20/2020 - 13:08
Scientific research advances at a good pace. Here are the most advanced treatments for the COVID-19 virus.
Patents Protect Innovation
By - Wed, 09/05/2018 - 10:02
Misconceptions about patents are common, with some people seeing them as a barrier to innovation, especially in the pharmaceutical segment.
Pharmaceuticals, Life Sciences, and Mexico’s New Health Economy
By - Wed, 09/09/2015 - 12:39
Mexico Health Summit 2015: Pharmaceuticals, Life Sciences, and Mexico’s New Health Economy Panel highlights
Certification Brings More Clinical Trials
By - Wed, 09/09/2015 - 12:29
The clinical trials industry in Mexico is expanding, and more collaboration among key players is necessary to promote further development.
Dolutegravir from Glaxosmithline
By - Sat, 09/05/2015 - 12:31
Around 35.3 million people worldwide have been infected by the Human Immunodeficiency Virus (HIV) with thousands more being infected every year.
Adding Value in a Dynamic and Diversified Market
By - Sat, 09/05/2015 - 12:07
Mexico is usually considered an emerging country, but the Mexican pharmaceutical market is in many respects mature